Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 78Neoplasms 69Prostatic Neoplasms 51Colorectal Neoplasms 45Lung Neoplasms 39Carcinoma, Non-Small-Cell Lung 28Hematologic Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 15Ovarian Neoplasms 15Multiple Myeloma 15Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Motor Activity 11Leukemia, Myeloid, Acute 11Glioblastoma 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Gastrointestinal Neoplasms 9Colonic Neoplasms 9Melanoma 8Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Esophageal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8

Interventions

Abiraterone Acetate 7enzalutamide 6olaparib 5Prednisone 5Pluvicto 5Docetaxel 5radium Ra 223 dichloride 4darolutamide 4cabazitaxel 3Prednisolone 3testosterone 17 beta-cypionate 2fludarabine 2abiraterone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1niraparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Standard of Care × Clear all
NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

Phase 2 Recruiting
162 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡